News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Pharm Country
FDA to Review Heart Risks of Parkinson’s Drug
August 20, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- The U.S. Food and Drug Administration said on Friday it will examine the potential heart risks of Novartis AG's (NOVN.VX) Parkinson's drug Stalevo, a combination of two treatments for the debilitating brain disease.
Twitter
LinkedIn
Facebook
Email
Print
MORE ON THIS TOPIC
Genetown
The Best Way to Answer Salary Interview Questions
June 11, 2024
·
4 min read
·
Lorenzo Soliman
Job Trends
Life Sciences R&D, Manufacturing Talent Becoming More Difficult to Find: Report
June 6, 2024
·
3 min read
·
Greg Slabodkin
Drug Development
Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial
May 3, 2024
·
2 min read
·
Tyler Patchen
Business
BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases
April 29, 2024
·
2 min read
·
Tyler Patchen
